Microbix Biosystems (TSX:MBX) has appointed Cameron Groome as its president and CEO, with Vaughn Embro-Pantalony retiring from those positions but remaining an executive director, working closely with Mr. Groome to ensure a smooth leadership transition.Read More
Oxford Immunotec Global (NASDAQ:OXFD) has appointed Karen Koski as head of strategy and investor relations, a newly created position that will report directly to CEO, Peter Wrighton-Smith. The appointment is effective on June 21.Read More
3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) appointed Dr. Kevin Little, a leading biomedical scientist and corporate executive, as its new chief scientific officer, effective immediately.Read More
Oppenheimer & Co., a unit of Oppenheimer Holdings (NYSE:OPY), has hired a new life sciences team, led by Michael Margolis, to join the firm's healthcare investment banking group.Read More
3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) has appointed Harry Glorikian to its business advisory board.Read More
Kenneth Galbraith, an accomplished life sciences industry veteran, has been appointed a director of Profound Medical (TSX-V:PRN).Read More
Microbix Biosystems (TSX:MBX) has signed a distribution agreement with Meridian Life Science, a wholly owned unit of Meridian Bioscience (NASDAQ:VIVO), a fully integrated global diagnostic and life sciences company.Read More
John Chambers has joined H.C. Wainwright as president and head of investment banking.Read More
Jeff Sacher has joined Aegis Capital to lead the firm's global healthcare effort as a managing director.
Previously, Mr. Sacher was a senior banker at Goldman Sachs, Needham and Brean Capital. In addition, he has served as CFO for Viacell, a stem cell company purchased by PerkinElmer.Read More
3D Signatures (TSX-V:DXD) has appointed Jason Flowerday as CEO. He succeeds Ferenc Somogyvari, who will remain on the board.
"Mr. Flowerday is a highly respected biotech entrepreneur with more than 20 years of executive life sciences management and startup experience. He has the entrepreneurial and management skills we need to drive us to commercialization," John Swift, chairman, said in a statement.Read More
BioLight Life Sciences (TASE:BOLT) reported promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology.
The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage.Read More
Anavex Life Sciences (NASDAQ:AVXL) presented safety data for its ANAVEX 2-73 drug candidate at the Alzheimer’s Association International Conference 2016 in Toronto.
Data presented in a poster highlights the evaluation of a maximum tolerated dose of ANAVEX 2-73 as primary endpoint of the Phase 2a study in mild-to-moderate Alzheimer’s patients, as well as additional clinical safety data and positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities through 31 weeks.Read More
The FDA has granted orphan drug designation to Anavex Life Sciences’ (NASDAQ:AVXL) ANAVEX 2-73 for the treatment of Rett syndrome.
In a statement, Christopher Missling, president and CEO, said orphan drug designation marks the first U.S. movement for ANAVEX 2-73.Read More
BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications.
The product was in-licensed from Fischer Pharmaceuticals and RAMOT, the technology transfer arm of the Tel Aviv University.Read More
Shaunak Deepak has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group.
Mr. Deepak previously was a VP and biotech analyst with Jefferies since 2009. He also has been an associate in the life sciences equity research departments of Piper Jaffray, Rodman & Renshaw and Stifel, Nicolaus.Read More
Closely-held NovellusDx of Israel has appointed Heiner Dreismann and Dr. Charles Woler to the board.
“The appointment of Drs. Dreismann and Woler, both venerated leaders in the biotech and pharma industries, with strong track records of success, is consistent with our effort to bring the best talent to NovellusDx and rapidly become the leader in personalized medicine,” CEO, Haim Gil-Ad, said in a statement.Read More